BACKGROUND: Paclitaxel (Taxol) is a novel chemotherapeutic agent, active against a variety of tumors. It is not known whether the drug penetrates brain tumor tissue. PATIENTS AND METHODS: Three patients with a recurrent glioma received paclitaxel (175 mg/m2) in a 3-hour i.v. infusion prior to surgery. Paclitaxel concentrations were measured in the tumor tissue, cerebrospinal fluid, cyst fluid, plasma and, in one patient, normal brain tissue. RESULTS: Tumor tissue concentrations were in the therapeutic range in all three patients. Brain tissue concentration, however, was below the detection limit of the trial. CONCLUSIONS: These findings suggest that paclitaxel may have a place in brain tumor therapy. The low concentration in normal brain ti...
The pharmacokinetics of single intraperitoneal doses of paclitaxel (18 and 36 mg/kg) in mice were in...
Taxanes are an important new class of anticancer agents that inhibit cell division by the unique...
Current chemotherapeutic approaches to recurrent head and neck cancer have routinely yielded respons...
Paclitaxel concentrations in the brain are very low after intravenous injection. Since paclitaxel is...
Background: Brain tumor vasculature can be significantly compromised and leakier than that of normal...
Princeton, NJ) is a new antineoplastic drug with broad-spectrum activity in solid tumors, including ...
Background: Glioma is the most common primary tumor of the central nervous system, and accounted for...
Paclitaxel (Taxol®) is a member of the taxane class of anticancer drugs and one of the most common c...
Background: Glioma is the most common primary tumor of the central nervous system, and accounted for...
Objectives Paclitaxel is a potent anti-cancer drug that has exhibited clinical activity against seve...
In situ brain perfusion were used to assess the brain uptake of our conjugates. Analysis of tissues ...
O paclitaxel é utilizado amplamente no carcinoma de ovário, nos casos refratários de carcinoma de en...
Background: Breast cancer (BC) is the most frequent malignant tumor in females and the 2nd most comm...
Paclitaxel is a chemotherapeutic drug which has clinical activity against several solid tumours incl...
textabstractIt has been hypothesized that the paclitaxel vehicle Cremophor EL (CrEL) is respon...
The pharmacokinetics of single intraperitoneal doses of paclitaxel (18 and 36 mg/kg) in mice were in...
Taxanes are an important new class of anticancer agents that inhibit cell division by the unique...
Current chemotherapeutic approaches to recurrent head and neck cancer have routinely yielded respons...
Paclitaxel concentrations in the brain are very low after intravenous injection. Since paclitaxel is...
Background: Brain tumor vasculature can be significantly compromised and leakier than that of normal...
Princeton, NJ) is a new antineoplastic drug with broad-spectrum activity in solid tumors, including ...
Background: Glioma is the most common primary tumor of the central nervous system, and accounted for...
Paclitaxel (Taxol®) is a member of the taxane class of anticancer drugs and one of the most common c...
Background: Glioma is the most common primary tumor of the central nervous system, and accounted for...
Objectives Paclitaxel is a potent anti-cancer drug that has exhibited clinical activity against seve...
In situ brain perfusion were used to assess the brain uptake of our conjugates. Analysis of tissues ...
O paclitaxel é utilizado amplamente no carcinoma de ovário, nos casos refratários de carcinoma de en...
Background: Breast cancer (BC) is the most frequent malignant tumor in females and the 2nd most comm...
Paclitaxel is a chemotherapeutic drug which has clinical activity against several solid tumours incl...
textabstractIt has been hypothesized that the paclitaxel vehicle Cremophor EL (CrEL) is respon...
The pharmacokinetics of single intraperitoneal doses of paclitaxel (18 and 36 mg/kg) in mice were in...
Taxanes are an important new class of anticancer agents that inhibit cell division by the unique...
Current chemotherapeutic approaches to recurrent head and neck cancer have routinely yielded respons...